Solid Biosciences Inc.
NASDAQ:SLDBBiotechnology
+$0.27 today
- Market cap
- $695.33M
- Beta
- 2.43
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$1.75
Volume 1.13M
Average 1.39M
SLDB Interest Income
Income earned on cash, deposits, and investments held by the company.
Solid Biosciences Inc.NASDAQ: SLDB
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income dips below year-ago levels
Q1 FY2026 interest income of $2.06M fell 10.3% year over year, behind the +6.0% change in trailing-twelve-month interest income. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at +55.9% a year.
Context
- Interest income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -10.3% toward the trailing-twelve-month pace of +6.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 9.9M USD
- Year-over-year change
- +4.6%
- 4-year CAGR
- +252.7%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.9M | +4.6% |
| FY2024 | 2024-12-31 | 9.47M | +32.6% |
| FY2023 | 2023-12-31 | 7.14M | +173.0% |
| FY2022 | 2022-12-31 | 2.62M | +3987.5% |
| FY2021 | 2021-12-31 | 64K | — |
Interest Income vs competitors
How SLDB compares with its peers on the latest reported figures
- SLDB's LTM Mar 2026 interest income of $9.66M is the 6th highest of the 10 companies compared; the peer median is $10.6M.
- Its year-over-year change of +6.0% is the 5th highest of 9, against a peer median of -11.7%.
- Over three fiscal years its annual growth of +55.9% compares with a peer median of +100.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $32.68M | +6.8% | +117.1% | — | |
| LTM Sep 2026 | $31.98M | +34.8% | +106.9% | — | |
| LTM Mar 2026 | $30.91M | -51.9% | -11.0% | 1.4% | |
| LTM Mar 2026 | $18.76M | -30.2% | +96.3% | 21.3% | |
| LTM Mar 2026 | $10.6M | +13.3% | +105.2% | — | |
| LTM Mar 2026 | $9.66M | +6.0% | +55.9% | — | |
| LTM Mar 2026 | $8.43M | +242.7% | +128.9% | — | |
| LTM Mar 2026 | $4.15M | -36.5% | +12.9% | — | |
| LTM Mar 2026 | $1.04M | -74.2% | +32.8% | 1.3% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding SLDB) | $10.6M | -11.7% | +100.8% | 1.4% | |
Competitors are the stored peer set for SLDB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 13.62M | 8.09M | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 2.58M | 2.46M | 1.64M |
| Gross Profit | 13.62M | 8.09M | (2.58M) | (2.46M) | (1.64M) |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 58.74M | 78.42M | 76.56M | 96.43M | 140.33M |
| Selling, General & Admin | 27.14M | 28.95M | 27.75M | 33.3M | 38.88M |
| Operating Expenses | 85.87M | 114.55M | 101.73M | 127.27M | 177.57M |
| Depreciation & Amortization | 2.96M | 2.41M | 2.58M | 2.46M | 1.64M |
| EBITDA | (69.22M) | (96.87M) | (93.43M) | (121.9M) | (172.69M) |
| EBITDA Margin | -508.3% | -1196.8% | — | — | — |
| Operating Income | (72.25M) | (106.45M) | (104.32M) | (129.73M) | (179.21M) |
| Operating Margin | -530.5% | -1315.2% | — | — | — |
| Interest Income | 64K | 2.62M | 7.14M | 9.47M | 9.9M |
| Interest Expense | 0 | 0 | 0 | 340K | 0 |
| Other Income / Expenses | 66K | 20.47M | 8.3M | 5.03M | 4.88M |
| Income Before Tax | (72.19M) | (85.98M) | (96.02M) | (124.7M) | (174.33M) |
| Pre-Tax Margin | -530.0% | -1062.3% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.19M) | (85.98M) | (96.02M) | (124.7M) | (174.33M) |
| Net Margin | -530.0% | -1062.3% | — | — | — |
| EPS (Basic) | (10.14) | (10.10) | (4.83) | (3.06) | (1.99) |
| EPS (Diluted) | (10.14) | (10.10) | (4.83) | (3.06) | (1.99) |
| Weighted Avg Shares | 7.12M | 8.51M | 19.88M | 40.82M | 87.5M |
| Weighted Avg Shares (Diluted) | 7.12M | 8.51M | 19.88M | 40.82M | 87.5M |
Solid Biosciences Inc.
NASDAQ:SLDB
Intrinsic Alpha fair value
Locked
Current Price
$6.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.